Insulins Will Be Manufactured In Uzbekistan Under GEROPHARM Technology

On April 25, at the Platform of INNOPROM. Central Asia International Industrial Trade Fair, the Ministry of Health of the Republic of Uzbekistan, GEROPHARM and ZUMA PHARMA (Uzbekistan) signed a cooperation agreement.

On April 25, at the Platform of INNOPROM. Central Asia International Industrial Trade Fair, the Ministry of Health of the Republic of Uzbekistan, GEROPHARM and ZUMA PHARMA (Uzbekistan) signed a cooperation agreement, which provides for technology transfer and localisation of production of insulin analogues and human insulins in the Republic of Uzbekistan.

The signing ceremony was attended by Denis Manturov, Minister of Industry and Trade of the Russian Federation and Sardor Umurzakov, Deputy Prime Minister of the Republic of Uzbekistan for Investments and International Economic Relations, Minister for Investments and International Trade.

The agreement is a strategic one as it identifies key areas of cooperation in the field of insulin production in Uzbekistan.

According to statistics provided by the Specialised Medical and Research Centre of Endocrinology with the Ministry of Health of the Republic of Uzbekistan, there are more than 277,000 diabetic patients in the country; more than 3,000 of them are children and adolescents under 18 years of age. With the investment project implemented, diabetic patients in Uzbekistan will get access to advanced, effective and affordable insulin products.

Considering the need to develop domestic biotechnological production and ensure sustainability of drug supply in Uzbekistan, GEROPHARM will transfer the technology for production of insulin analogues and human insulins to ZUMA PHARMA site, with a further prospect of localisation of finished dosage form production.

In order to implement the agreement, a working group will be formed and a project implementation programme developed (roadmap) to determine cooperation terms and time frames.

Pyotr Rodionov, General Director, GEROPHARM, says, “GEROPHARM has a proven experience in insulin production technology transfer to other countries. We are willing to continue sharing our expertise and technologies in this sphere as hundreds of thousands of diabetic patients depend on daily insulin injections. Currently, we do our best to cover the need of Russian patients who use GEROPHARM insulins and to set up insulin production abroad. We believe that life of each patient matters and as long as we can, we feel it our duty to help resolve this burning issue of social importance.”

In addition to the technological support, GEROPHARM will continue helping improve competence of medical healthcare professionals in Uzbekistan.

Starting from April 1, a new model of medical observation and nursing is adopted in the country in order to ensure early diagnosis and targeted observation of endocrine pathologies. Under the new model, physicians will get further training in diagnosing and treating endocrine pathologies.

International dialogues, including meetings of Russian and Uzbekistan specialists, creation of scientific, educational, and research environment for development and implementation of joint projects are instrumental in addressing this challenge.

In February 2022, GEROPHARM assisted in arranging the visit to the Russian Federation for F.F. Turaev, Director, Specialised Medical and Research Centre of Endocrinology with the Ministry of Health of the Republic of Uzbekistan, and F.A. Haydarova, Chief Endocrinologist of Uzbekistan, for a number of meetings at leading medical centres in Russia. The visit resulted in two cooperation agreements (with National Medical Research Centre for Endocrinology, Minzdrav of Russia, and Almazov National Medical Research Centre, Minzdrav of Russia). Currently, an education project for diabetes prevention and treatment aimed at both physicians and patients is about to be launched.